Skip to main content
Premium Trial:

Request an Annual Quote

HBIO to Divest Capital Equipment Business; Postpones Q2 Earnings Report

NEW YORK, July 28 (GenomeWeb News) - Harvard Bioscience plans to divest its capital equipment business, which includes the Genomic Solutions product line, the company said yesterday.

 

HBIO also said it has postponed its second-quarter earnings report, originally scheduled for today, until Aug. 8. This will allow the company to complete a review of whether the capital equipment business segment met the criteria for "held for sale" accounting treatment as of June 30 under GAAP financial statement rules.

 

HBIO said that second-quarter results for the capital equipment business, which includes the COPAS and Genomic Solution product lines, "fell short of the company's expectations." As a result, HBIO expects to record "significant impairment charges related to goodwill and other intangible assets" as well as "significant charges related to the previously announced restructuring activities."

 

The way in which these charges will be presented in the second-quarter earnings will depend on the outcome of the review, according to the company.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.